Navigation Links
Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Date:9/5/2007

h respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

For Gen
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
2. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
3. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
4. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
5. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
8. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014  Neuland Laboratories Ltd., (NSE:NEULANDLAB; ... pharmaceutical ingredients (APIs), complex intermediates and ... 85 countries, today announced financial results for the ... June 30, 2014. "Neuland,s results in ... re-prioritization to accommodate certain customer needs, and we ...
(Date:8/1/2014)... Aug. 1, 2014 Arena Pharmaceuticals, Inc. ... corporate update and reported financial results for the ... "We have continued to see encouraging advancements ... 43% quarter-over-quarter increase in estimated total prescriptions and ... mark," said Jack Lief, Arena,s President and Chief ...
(Date:7/31/2014)... -- According to data released today by the Centers for ... Part D premium is expected to remain stable at ... the Pharmaceutical Care Management Association (PCMA) said. ... bright spot in American health care. By offering an ... cutting edge, cost-saving tools like pharmacy networks and home ...
Breaking Medicine Technology:Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
... R.I., Oct. 15 CVS/pharmacy announced today that its ... in light of manufacturer delays in delivery of seasonal ... MinuteClinic will continue to administer seasonal flu vaccines at ... season with the supply of vaccine replenished as frequently ...
... Inc. (Nasdaq: CYNO ), a leading developer ... systems, today announced that the company will host its third-quarter ... a.m. ET. , On the call, President and Chief Executive ... Officer Timothy Baker will discuss Cynosure,s financial results, as well ...
Cached Medicine Technology:CVS Caremark Announces Updates to Flu Vaccine Program 2CVS Caremark Announces Updates to Flu Vaccine Program 3Cynosure to Announce Third-Quarter 2009 Financial Results on October 27 2
(Date:8/1/2014)... Cannabis use among young people has spiked, ... 17 having used marijuana at least once and 17 percent ... ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from the ... this summer with factual information about drugs, to help reverse ... “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers have ...
(Date:8/1/2014)... of Medicine in St. Louis helps explain why brain ... more harmful than similar tumors in females. For example, ... twice as often in males, who suffer greater cognitive ... , The researchers found that retinoblastoma protein (RB), a ... active in male brain cells than in female brain ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay ... who are obese and work in manufacturing jobs may have significantly ... In a study of 32 people -- half were obese, ... had endurance times that were about 60 percent longer. Obesity ... task performance. Being older -- 50 to 65 ...
(Date:8/1/2014)... 2014 (HealthDay News) -- Almost 140 people die ... in the United States. But there are ... Dawne Gardner, injury prevention coordinator at Cincinnati Children,s ... in a medical center news release. "As ... school, it,s important for parents and children to ...
(Date:8/1/2014)... Summer is here, and with it comes the ... and they can be a pain for dogs. Animal Emergency ... their customers get rid of ticks and prevent them completely. ... the summer, which is why they are so active during ... woodland areas and carry a number of diseases, including lyme ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2
... TAMPA, Fla. -- Alexander R. A. Anderson, Ph.D., co-director ... and his colleagues, Simon Hayward, Ph.D., at Vanderbilt University ... have received a five-year, $3 million grant from the ... to predict prostate cancer aggressiveness. "Mathematical models have ...
... HealthDay Reporter , THURSDAY, Oct. 20 (HealthDay News) -- The ... worry about an increased risk of brain cancer, new Danish research ... subject finds no more brain tumors among people who had cell ... phones. Although no one study can rule out harm with ...
... HealthDay Reporter , FRIDAY, Oct. 21 (HealthDay News) ... hormone production as the testes and adrenal glands. But those ... new study, showing hormone production in the penis itself, turn ... in both mice and human tissue, revealing that proteins key ...
... new development paths towards a healthier life. New opportunities ... development, industrial biotechnology and environmental technology have been a ... , VTT is one of the organisers of Metabomeeting ... at the end of September. Professor Jeremy K. Nicholson ...
... scientists advances a strategy for taming the side effects ... medications that work by disrupting the activity of certain ... developed at St. Jude. In this study, scientists showed ... activity of genes in a cell signaling pathway regulated ...
... over the years has made it possible for researchers and ... using ionising radiation, for example X-rays. The images ... of water in the body, since the body is largely ... nuclei in water molecules. It can also be used to ...
Cached Medicine News:Health News:Researchers get $3 million National Institutes of Health grant for mathematical models of prostate cancer aggressiveness 2Health News:Cell Phones Don't Raise Brain Cancer Risk, Study Says 2Health News:Cell Phones Don't Raise Brain Cancer Risk, Study Says 3Health News:Research Suggests Penis Might Produce Testosterone 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 3Health News:New instrument helps researchers see how diseases start and develop in minute detail 2
The Ceracup has a standard profile plastic component with a ceramic insert and the benefit of alumina-alumina contact....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Medicine Products: